Skip to content

Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms

Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Lotion) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Sunburn Related Symptoms

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01085851
Enrollment
30
Registered
2010-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2010-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sunburn

Keywords

Sunburn, Dexchlorpheniramine, Lotion, Cream

Brief summary

Topical antihistamines can be used to promote relief of sunburn related symptoms (erythema, itch and burning sensations). Dexchlorpheniramine maleate 1% cream is a topical antihistamine formulation approved by ANVISA in Brazil for the relief of skin irritation and pruritus, including the ones caused by sunburn. The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% lotion) with the standard preparation (1% cream) for the relief of sunburn related symptoms and to demonstrate the safety of both preparations.

Interventions

Small amount applied over the lesion twice a day for 7 days

Small amount applied over the lesion twice a day for 7 days

Sponsors

Mantecorp Industria Quimica e Farmaceutica Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Signs of solar erythema of mild to moderate intensity resulting from voluntary exposure to sun within the last 72 hours * Presence of lesions with some degree of symmetry to allow comparison between both pharmaceutical formulations * Compliance of the subject to the treatment protocol * Agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old

Exclusion criteria

* Pregnancy or risk of pregnancy * Lactation * Signs of solar erythema of severe intensity * Use of topical or systemic anti-inflammatory, antihistamine or immunosuppressive drugs within the last 48 hours prior to the study * History of atopy or allergic diseases * History of allergy to any component of the formulations * Other conditions considered by the investigator as reasonable for non-eligibility

Design outcomes

Primary

MeasureTime frame
Pruritus intensity evaluated with a 10-point Visual Analogic Scale (VAS)7 days

Secondary

MeasureTime frame
Composite clinical evaluation of erythema, pruritus and burning sensation performed by the investigator using a 4-point scale for each one of the variables (absent, mild, moderate, intense).7 days

Countries

Brazil

Contacts

Primary ContactSérgio Schalka, MD
+551136811334

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026